ID21881A - NEW PIRAZOL SUBSTITUTED PURAZOLS - Google Patents

NEW PIRAZOL SUBSTITUTED PURAZOLS

Info

Publication number
ID21881A
ID21881A IDW990388A ID990388A ID21881A ID 21881 A ID21881 A ID 21881A ID W990388 A IDW990388 A ID W990388A ID 990388 A ID990388 A ID 990388A ID 21881 A ID21881 A ID 21881A
Authority
ID
Indonesia
Prior art keywords
purazols
pirazol
substituted
new
substituted purazols
Prior art date
Application number
IDW990388A
Other languages
Indonesian (id)
Inventor
Alexander Straub
Chantal Furstner
Thomas Jaetsch
Achim Feurer
Raimund Kast
Johannes Peter Stasch
Elisabeth Perzborn
Joachim Hutter
Klaus Dembowsky
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ID21881A publication Critical patent/ID21881A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDW990388A 1996-11-26 1997-11-14 NEW PIRAZOL SUBSTITUTED PURAZOLS ID21881A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19649460A DE19649460A1 (en) 1996-11-26 1996-11-26 New substituted pyrazole derivatives

Publications (1)

Publication Number Publication Date
ID21881A true ID21881A (en) 1999-08-05

Family

ID=7813100

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW990388A ID21881A (en) 1996-11-26 1997-11-14 NEW PIRAZOL SUBSTITUTED PURAZOLS

Country Status (26)

Country Link
EP (1) EP0944631B1 (en)
JP (2) JP4422800B2 (en)
CN (1) CN1122032C (en)
AR (1) AR010310A1 (en)
AT (1) ATE259812T1 (en)
AU (1) AU729642B2 (en)
BR (1) BR9714363A (en)
CA (1) CA2272584C (en)
CZ (1) CZ185099A3 (en)
DE (2) DE19649460A1 (en)
DK (1) DK0944631T3 (en)
EE (1) EE9900211A (en)
ES (1) ES2214646T3 (en)
HK (1) HK1023119A1 (en)
HU (1) HUP0000562A3 (en)
ID (1) ID21881A (en)
IL (1) IL129998A0 (en)
MX (1) MXPA99004826A (en)
NO (1) NO992400L (en)
NZ (1) NZ335890A (en)
PT (1) PT944631E (en)
SK (1) SK67699A3 (en)
TR (1) TR199901172T2 (en)
TW (1) TW403746B (en)
WO (1) WO1998023619A1 (en)
ZA (1) ZA9710573B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19744026A1 (en) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazole derivatives, their preparation and their use in medicinal products
DE19827679A1 (en) * 1998-06-22 1999-12-23 Dresden Arzneimittel New pyrazolo(3,4-d)pyrimidine derivative adenosine A3 receptor antagonists, used for treating epilepsy, asthma or allergy
DE19834047A1 (en) * 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19834044A1 (en) * 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
DE19834045A1 (en) * 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl) -1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b] pyridine
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19920352A1 (en) * 1999-05-04 2000-11-09 Bayer Ag Substituted pyrazole derivative
DE19943636A1 (en) 1999-09-13 2001-03-15 Bayer Ag Novel dicarboxylic acid derivatives with pharmaceutical properties
DE19943634A1 (en) 1999-09-13 2001-04-12 Bayer Ag Novel dicarboxylic acid derivatives with pharmaceutical properties
DE19943635A1 (en) * 1999-09-13 2001-03-15 Bayer Ag Novel aminodicarboxylic acid derivatives with pharmaceutical properties
DE10021069A1 (en) * 2000-04-28 2001-10-31 Bayer Ag Substituted pyrazole derivative
DE10057754A1 (en) 2000-11-22 2002-05-23 Bayer Ag New cyclic sulfonamido-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
JP4295505B2 (en) 2000-11-22 2009-07-15 バイエル アクチェンゲゼルシャフト New lactam substituted pyrazolopyridine derivatives
DE10057751A1 (en) 2000-11-22 2002-05-23 Bayer Ag New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation
AR031176A1 (en) 2000-11-22 2003-09-10 Bayer Ag NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE
DE10109858A1 (en) 2001-03-01 2002-09-05 Bayer Ag Novel halogen-substituted aminodicarboxylic acid derivatives
DE10109861A1 (en) 2001-03-01 2002-09-05 Bayer Ag Novel side chain halogenated aminodicarboxylic acid derivatives
DE10110749A1 (en) * 2001-03-07 2002-09-12 Bayer Ag Substituted aminodicarboxylic acid derivatives
DE10122894A1 (en) 2001-05-11 2002-11-14 Bayer Ag New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
DE10132416A1 (en) * 2001-07-04 2003-01-16 Bayer Ag New morpholine-bridged pyrazolopyridine derivatives
DE10220570A1 (en) 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
DE10232572A1 (en) * 2002-07-18 2004-02-05 Bayer Ag New 2,5-disubstituted pyrimidine derivatives
DE10244810A1 (en) * 2002-09-26 2004-04-08 Bayer Ag New morpholine-bridged indazole derivatives
WO2005030121A2 (en) * 2003-06-30 2005-04-07 Hif Bio, Inc. Compounds, compositions and methods
DE102005050377A1 (en) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclic compounds and their use
DE102005050375A1 (en) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazole derivatives and their use
DE102005050498A1 (en) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylacetic acid derivatives and their use
DE102005050376A1 (en) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarboxylic acid derivatives and their use
DE102005050497A1 (en) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorophenol derivatives and their use
DE102006020327A1 (en) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclic substituted, fused pyrazole derivatives and their use
DE102006043443A1 (en) 2006-09-15 2008-03-27 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
DE102007015034A1 (en) 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituted dicarboxylic acids and their use
DE102007015035A1 (en) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituted dibenzoic acid derivatives and their use
DE102007026392A1 (en) 2007-06-06 2008-12-11 Bayer Healthcare Ag Solutions for the perfusion and preservation of organs and tissues
DE102007028407A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007028406A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007028319A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007028320A1 (en) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
PT2294066E (en) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
EP2138178A1 (en) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
DE102008063992A1 (en) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. New aliphatic substituted pyrazolopyridines and their use
DE102009004245A1 (en) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Novel fused, heteroatom-bridged pyrazole and imidazole derivatives and their use
UY33041A (en) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINO-2- [1- (2-FLUOROBENCIL) -1H-PIRAZOLO [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} CARBAMATO DE METTILO AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
WO2012143510A1 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoroalkyl-substituted pyrazolopyridines and use thereof
EP2755974A1 (en) 2011-09-14 2014-07-23 Proximagen Limited New enzyme inhibitor compounds
EP3112363A1 (en) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
EA201792346A1 (en) 2015-05-06 2018-05-31 Байер Фарма Акциенгезельшафт APPLICATION of sGC STIMULATORS, sGC ACTIVATORS, SEPARATELY AND IN COMBINATION WITH PDE5 INHIBITORS, FOR THE TREATMENT OF PALCULAR ULCER (DU), ASSOCIATED TO SYSTEMIC SCLEROSE (SSc)
SI3325013T2 (en) 2015-07-23 2023-11-30 Bayer Pharma Aktiengesellschaft Stimulators / activators of soluble guanylat cyclase in combination with a nep-inhibitor and/or an angiotensin aii-antagonist and the use thereof
EA201891416A1 (en) 2015-12-14 2018-12-28 Айронвуд Фармасьютикалз, Инк. APPLICATION of sGC STIMULATORS FOR THE TREATMENT OF GASTRIC AND INTESTINAL SPINKLIN TREATMENT
WO2017121700A1 (en) * 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituted 1h-pyrazolo[3,4-b]pyridine derivatives and use thereof as stimulators of soluble guanylate cyclase
JP7237823B2 (en) 2016-10-11 2023-03-13 バイエル ファーマ アクチエンゲゼルシャフト Combinations comprising SGC activators and mineralocorticoid receptor antagonists
US10918639B2 (en) 2016-10-11 2021-02-16 Bayer Pharma Aktiengesellschaft Combination containing SGC stimulators and mineralocorticoid receptor antagonists
US20190381039A1 (en) 2016-12-13 2019-12-19 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
AU2018252099B2 (en) 2017-04-11 2021-08-12 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
BR112020022340A2 (en) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamides replaced by 1,3-thiazol-2-yl for the treatment of diseases associated with nerve fiber sensitization
US20210177846A1 (en) 2018-07-11 2021-06-17 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0615542B2 (en) * 1986-07-22 1994-03-02 吉富製薬株式会社 Pyrazolopyridine compound
US4994482A (en) * 1989-07-31 1991-02-19 Bristol-Myers Squibb Company Arylpyrazol derivatives as anti-platelet agents, compositions and use
WO1993023036A1 (en) * 1992-05-21 1993-11-25 Yoshitomi Pharmaceutical Industries, Ltd. Optically active condensed pyrazole compound for use in treating thrombocytopenia and erythropenia
JP2928079B2 (en) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1- (Substituted benzyl) -3- (substituted aryl) condensed pyrazoles, their production and use
CN1039536C (en) * 1994-02-28 1998-08-19 永信药品工业股份有限公司 1,3 substituted condensed pyrazole compound, the application and prepn. method

Also Published As

Publication number Publication date
JP2010013475A (en) 2010-01-21
HK1023119A1 (en) 2000-09-01
NO992400D0 (en) 1999-05-19
ES2214646T3 (en) 2004-09-16
BR9714363A (en) 2000-03-21
EP0944631B1 (en) 2004-02-18
DE59711321D1 (en) 2004-03-25
CA2272584C (en) 2007-10-16
ZA9710573B (en) 1998-06-10
HUP0000562A2 (en) 2000-10-28
WO1998023619A1 (en) 1998-06-04
IL129998A0 (en) 2000-02-29
SK67699A3 (en) 2000-02-14
EE9900211A (en) 1999-12-15
CN1122032C (en) 2003-09-24
NZ335890A (en) 2001-02-23
DE19649460A1 (en) 1998-05-28
CN1238773A (en) 1999-12-15
MXPA99004826A (en) 2008-02-19
HUP0000562A3 (en) 2001-12-28
NO992400L (en) 1999-05-19
JP2001505567A (en) 2001-04-24
PT944631E (en) 2004-06-30
AU5482398A (en) 1998-06-22
ATE259812T1 (en) 2004-03-15
AR010310A1 (en) 2000-06-07
CZ185099A3 (en) 1999-08-11
JP4422800B2 (en) 2010-02-24
TW403746B (en) 2000-09-01
TR199901172T2 (en) 1999-08-23
CA2272584A1 (en) 1998-06-04
EP0944631A1 (en) 1999-09-29
DK0944631T3 (en) 2004-06-07
AU729642B2 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
ID21881A (en) NEW PIRAZOL SUBSTITUTED PURAZOLS
ID17686A (en) NEW ALPHA-AMINOASETOFENON PHOTOINISIATOR
ID15840A (en) NEW 19-NOR-PREGNENA DESIGNS
ID15881A (en) NEW SUBSTITUTED OCTZOLIDINANT
ID18759A (en) IMIDAZOLE SUBSTITUTED NEW CYCLALKIL
ID27263A (en) NEW HYDROPIRIMIDINE
ID15880A (en) NEW FORM OF HETEROARIL OKSAZOLIDINON-OKSAZOLIDINON
ID17873A (en) NEW TROMBIN HANDLER
ID18431A (en) NEW COMPOUNDS
ID16660A (en) NEW MONOSICLIC B-LAKTAM COMPOUNDS
ID17421A (en) COMFORT NEW COMPOUND
ID26299A (en) NEW HERBISIDES
ID18262A (en) NEW PIRANOSIDES
ID19542A (en) NEW TREATMENT
ID16247A (en) NEW METHOD
DE59708449D1 (en) SUBSTITUTED P-TRIFLUORMETHYLPHENYLURACILE
ID19433A (en) NEW COMPOUNDS
ID24191A (en) NEW COMPOSITION
DE59707428D1 (en) SUBSTITUTED 1-METHYL-3-BENZYLURACILE
ID16684A (en) NEW SULFONILUREA COMPOUNDS
ATE275146T1 (en) SUBSTITUTED PYRAZOLE-3-YLBENZAZOLE
ID22144A (en) NEW COMPOUNDS
ID18889A (en) NEW COMPOUND
BR9711681A (en) New m-all
ID16373A (en) NEW COMPOUNDS